HRP20100522T1 - Piridin karboksamidi kao inhibitori 11-beta-hsd1 - Google Patents
Piridin karboksamidi kao inhibitori 11-beta-hsd1 Download PDFInfo
- Publication number
- HRP20100522T1 HRP20100522T1 HR20100522T HRP20100522T HRP20100522T1 HR P20100522 T1 HRP20100522 T1 HR P20100522T1 HR 20100522 T HR20100522 T HR 20100522T HR P20100522 T HRP20100522 T HR P20100522T HR P20100522 T1 HRP20100522 T1 HR P20100522T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyridin
- acetic acid
- propylsulfanyl
- cyclohexylcarbamoyl
- piperidyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- 125000005843 halogen group Chemical group 0.000 claims abstract 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 23
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 21
- 125000001424 substituent group Chemical group 0.000 claims abstract 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 19
- 239000001257 hydrogen Substances 0.000 claims abstract 19
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 18
- -1 phenylC1-3alkyl Chemical group 0.000 claims abstract 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 16
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 14
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 14
- 229910052717 sulfur Chemical group 0.000 claims abstract 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 13
- 239000001301 oxygen Chemical group 0.000 claims abstract 13
- 239000011593 sulfur Chemical group 0.000 claims abstract 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 11
- 125000005842 heteroatom Chemical group 0.000 claims abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract 6
- 125000004122 cyclic group Chemical group 0.000 claims abstract 6
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 6
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 3
- 125000005592 polycycloalkyl group Polymers 0.000 claims abstract 3
- 125000006413 ring segment Chemical group 0.000 claims abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 2
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 2
- 125000001589 carboacyl group Chemical group 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 124
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 47
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 24
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 7
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- OTVUUOKTGJTVOI-NXEDIBJZSA-N (3r,5s)-4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]amino]adamantane-1-carboxylic acid Chemical compound C1([C@]2([H])CC3C[C@]1(CC(C3)(C2)C(O)=O)[H])NC(N=C1SCCC)=CC=C1C(=O)NC1CCCCC1 OTVUUOKTGJTVOI-NXEDIBJZSA-N 0.000 claims 2
- MFLSCKDFADLNLG-FQEVSTJZSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-(3,4-dihydro-1h-isoquinolin-2-yl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1N2CC3=CC=CC=C3CC2)=CC=C1C(=O)NC1CCCCC1 MFLSCKDFADLNLG-FQEVSTJZSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 claims 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- WUYAHJJXCBDIKJ-NPWKZODJSA-N (1s,5r)-3-[5-(2-adamantylcarbamoyl)-6-ethylsulfanylpyridin-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid Chemical compound C1C(CC2C3)CC3CC1C2NC(=O)C1=CC=C(N2C[C@@H]3[C@@H](C3C(O)=O)C2)N=C1SCC WUYAHJJXCBDIKJ-NPWKZODJSA-N 0.000 claims 1
- HEAOWUYQOYGPJY-XDIGRCDVSA-N (1s,5r)-3-[6-cyclohexylsulfanyl-5-(3-pyridin-3-ylpyrrolidine-1-carbonyl)pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid Chemical compound C([C@@H]1C([C@@H]1C1)C(=O)O)N1C(N=C1SC2CCCCC2)=CC=C1C(=O)N(C1)CCC1C1=CC=CN=C1 HEAOWUYQOYGPJY-XDIGRCDVSA-N 0.000 claims 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 1
- KXRYVJZOORPUHV-BWVQPMQLSA-N (3r)-1-[5-(2-adamantylcarbamoyl)-6-ethylsulfanylpyridin-2-yl]pyrrolidine-3-carboxylic acid Chemical compound C=1C=C(C(=O)NC2C3CC4CC(C3)CC2C4)C(SCC)=NC=1N1CC[C@@H](C(O)=O)C1 KXRYVJZOORPUHV-BWVQPMQLSA-N 0.000 claims 1
- LPURRRBKLBZUPO-WFBUYENLSA-N (3r)-1-[5-(2-adamantylcarbamoyl)-6-methylsulfanylpyridin-2-yl]pyrrolidine-3-carboxylic acid Chemical compound C=1C=C(C(=O)NC2C3CC4CC(C3)CC2C4)C(SC)=NC=1N1CC[C@@H](C(O)=O)C1 LPURRRBKLBZUPO-WFBUYENLSA-N 0.000 claims 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 claims 1
- TUQXAEMHWYQEKQ-UHFFFAOYSA-N 1-[1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-4-yl]cyclobutane-1-carboxylic acid Chemical compound CCCSC1=NC(N2CCC(CC2)C2(CCC2)C(O)=O)=CC=C1C(=O)NC1CCCCC1 TUQXAEMHWYQEKQ-UHFFFAOYSA-N 0.000 claims 1
- ZLGMJDQCLXIRIW-UHFFFAOYSA-N 1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidine-4-carboxylic acid Chemical compound CCCSC1=NC(N2CCC(CC2)C(O)=O)=CC=C1C(=O)NC1CCCCC1 ZLGMJDQCLXIRIW-UHFFFAOYSA-N 0.000 claims 1
- IPWNSFXRBGOKPT-UHFFFAOYSA-N 1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]pyrrolidine-3-carboxylic acid Chemical compound CCCSC1=NC(N2CC(CC2)C(O)=O)=CC=C1C(=O)NC1CCCCC1 IPWNSFXRBGOKPT-UHFFFAOYSA-N 0.000 claims 1
- DLFCVUOKIZFDKH-IBWORTCRSA-N 2-[(3r)-1-[5-(2-adamantylcarbamoyl)-6-cyclopentylsulfanylpyridin-2-yl]pyrrolidin-3-yl]oxyacetic acid Chemical compound C1[C@H](OCC(=O)O)CCN1C(N=C1SC2CCCC2)=CC=C1C(=O)NC1C(C2)CC3CC2CC1C3 DLFCVUOKIZFDKH-IBWORTCRSA-N 0.000 claims 1
- SCSGTNXILYPGSQ-XMYZRKPFSA-N 2-[(3r)-1-[5-(2-adamantylcarbamoyl)-6-methylsulfanylpyridin-2-yl]pyrrolidin-3-yl]acetic acid Chemical compound C=1C=C(C(=O)NC2C3CC4CC(C3)CC2C4)C(SC)=NC=1N1CC[C@H](CC(O)=O)C1 SCSGTNXILYPGSQ-XMYZRKPFSA-N 0.000 claims 1
- CULOQDXMEBSGMA-OAHLLOKOSA-N 2-[(3r)-1-[5-(cyclohexylcarbamoyl)-3-fluoro-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound FC=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1N1CCC[C@H](CC(O)=O)C1 CULOQDXMEBSGMA-OAHLLOKOSA-N 0.000 claims 1
- NCDZABJPWMBMIQ-MRXNPFEDSA-N 2-[(3r)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@@H](CC(O)=O)CCC2)=CC=C1C(=O)NC1CCCCC1 NCDZABJPWMBMIQ-MRXNPFEDSA-N 0.000 claims 1
- UZTXBBWTQKNEIG-OAHLLOKOSA-N 2-[(3r)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]pyrrolidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@@H](CC(O)=O)CC2)=CC=C1C(=O)NC1CCCCC1 UZTXBBWTQKNEIG-OAHLLOKOSA-N 0.000 claims 1
- FLIPCDXQSSQHMS-SCUMNGBJSA-N 2-[(3s)-1-[5-(1-adamantylcarbamoyl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C1=CC=C(C(=O)NC23CC4CC(CC(C4)C2)C3)C=N1 FLIPCDXQSSQHMS-SCUMNGBJSA-N 0.000 claims 1
- KQLRCVBCXCJKNB-APWXSCSYSA-N 2-[(3s)-1-[5-(2-adamantylcarbamoyl)-6-cyclohexylsulfanylpyridin-2-yl]pyrrolidin-3-yl]oxyacetic acid Chemical compound C1[C@@H](OCC(=O)O)CCN1C(N=C1SC2CCCCC2)=CC=C1C(=O)NC1C(C2)CC3CC2CC1C3 KQLRCVBCXCJKNB-APWXSCSYSA-N 0.000 claims 1
- DLFCVUOKIZFDKH-KEBNJSOGSA-N 2-[(3s)-1-[5-(2-adamantylcarbamoyl)-6-cyclopentylsulfanylpyridin-2-yl]pyrrolidin-3-yl]oxyacetic acid Chemical compound C1[C@@H](OCC(=O)O)CCN1C(N=C1SC2CCCC2)=CC=C1C(=O)NC1C(C2)CC3CC2CC1C3 DLFCVUOKIZFDKH-KEBNJSOGSA-N 0.000 claims 1
- DEZDNNQATPOEGF-SXFOCMKRSA-N 2-[(3s)-1-[5-(2-adamantylcarbamoyl)-6-methylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C=1C=C(C(=O)NC2C3CC4CC(C3)CC2C4)C(C)=NC=1N1CCC[C@@H](CC(O)=O)C1 DEZDNNQATPOEGF-SXFOCMKRSA-N 0.000 claims 1
- OQGIUZADBRQLNO-HNNXBMFYSA-N 2-[(3s)-1-[5-(4,4-difluoropiperidine-1-carbonyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N1CCC(F)(F)CC1 OQGIUZADBRQLNO-HNNXBMFYSA-N 0.000 claims 1
- AGRNYJCBLOMLGJ-HNNXBMFYSA-N 2-[(3s)-1-[5-(4-carbamoylpiperidine-1-carbonyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N1CCC(C(N)=O)CC1 AGRNYJCBLOMLGJ-HNNXBMFYSA-N 0.000 claims 1
- CULOQDXMEBSGMA-HNNXBMFYSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-3-fluoro-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound FC=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1N1CCC[C@@H](CC(O)=O)C1 CULOQDXMEBSGMA-HNNXBMFYSA-N 0.000 claims 1
- MABNZVPFIQPNQO-FQEVSTJZSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-(2-pyridin-3-ylethylsulfanyl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1SCCC=2C=NC=CC=2)=CC=C1C(=O)NC1CCCCC1 MABNZVPFIQPNQO-FQEVSTJZSA-N 0.000 claims 1
- FAHINHOKFSWBQD-XHBOBUFASA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-(3-methylbutoxy)pyridin-2-yl]piperidin-3-yl]acetic acid;2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-(3-phenylpropoxy)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CC(C)CCOC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)NC1CCCCC1.C1[C@H](CC(=O)O)CCCN1C(N=C1OCCCC=2C=CC=CC=2)=CC=C1C(=O)NC1CCCCC1 FAHINHOKFSWBQD-XHBOBUFASA-N 0.000 claims 1
- YIVHEVFYXYIMQI-IBGZPJMESA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-(4-ethylsulfonylpiperazin-1-yl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1CN(S(=O)(=O)CC)CCN1C1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)NC1CCCCC1 YIVHEVFYXYIMQI-IBGZPJMESA-N 0.000 claims 1
- WEGLHTQFGNFPQQ-DEOSSOPVSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-(4-phenylmethoxycarbonylpiperazin-1-yl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1N2CCN(CC2)C(=O)OCC=2C=CC=CC=2)=CC=C1C(=O)NC1CCCCC1 WEGLHTQFGNFPQQ-DEOSSOPVSA-N 0.000 claims 1
- NYJBPBKPVXQXIF-QFIPXVFZSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-(4-phenylpiperazin-1-yl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1N2CCN(CC2)C=2C=CC=CC=2)=CC=C1C(=O)NC1CCCCC1 NYJBPBKPVXQXIF-QFIPXVFZSA-N 0.000 claims 1
- URDPPCFQBYGOEK-QUJONECCSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-[2-(4-fluorophenyl)ethoxy]pyridin-2-yl]piperidin-3-yl]acetic acid;2-[(3s)-1-[5-(cyclohexylcarbamoyl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C1=CC=C(C(=O)NC2CCCCC2)C=N1.C1[C@H](CC(=O)O)CCCN1C(N=C1OCCC=2C=CC(F)=CC=2)=CC=C1C(=O)NC1CCCCC1 URDPPCFQBYGOEK-QUJONECCSA-N 0.000 claims 1
- COVVXBQQRFUZQA-NRFANRHFSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-[4-(4-fluorobenzoyl)piperazin-1-yl]pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1N2CCN(CC2)C(=O)C=2C=CC(F)=CC=2)=CC=C1C(=O)NC1CCCCC1 COVVXBQQRFUZQA-NRFANRHFSA-N 0.000 claims 1
- LRBFVDFSHJWKQP-CRMCKAOTSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-[methyl(2-phenylethyl)amino]pyridin-2-yl]piperidin-3-yl]acetic acid;2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-[methyl(propyl)amino]pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCN(C)C1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)NC1CCCCC1.N=1C(N2C[C@H](CC(O)=O)CCC2)=CC=C(C(=O)NC2CCCCC2)C=1N(C)CCC1=CC=CC=C1 LRBFVDFSHJWKQP-CRMCKAOTSA-N 0.000 claims 1
- UVLKNKMJZSBROZ-HNNXBMFYSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-cyclopropylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1C2CC2)=CC=C1C(=O)NC1CCCCC1 UVLKNKMJZSBROZ-HNNXBMFYSA-N 0.000 claims 1
- ZRWLIWLEJVTMNH-KRWDZBQOSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-piperazin-1-ylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1N2CCNCC2)=CC=C1C(=O)NC1CCCCC1 ZRWLIWLEJVTMNH-KRWDZBQOSA-N 0.000 claims 1
- NCDZABJPWMBMIQ-INIZCTEOSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)NC1CCCCC1 NCDZABJPWMBMIQ-INIZCTEOSA-N 0.000 claims 1
- UZTXBBWTQKNEIG-HNNXBMFYSA-N 2-[(3s)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]pyrrolidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CC2)=CC=C1C(=O)NC1CCCCC1 UZTXBBWTQKNEIG-HNNXBMFYSA-N 0.000 claims 1
- AMSUENPUCKPGGN-GTPINHCMSA-N 2-[(3s)-1-[5-[(4-hydroxycyclohexyl)carbamoyl]-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)NC1CCC(O)CC1 AMSUENPUCKPGGN-GTPINHCMSA-N 0.000 claims 1
- QYVSMIVRWCSXAZ-SFHVURJKSA-N 2-[(3s)-1-[5-[cyclohexyl(cyclopropyl)carbamoyl]-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N(C1CCCCC1)C1CC1 QYVSMIVRWCSXAZ-SFHVURJKSA-N 0.000 claims 1
- ZMLDBFQNSHTHBA-FQEVSTJZSA-N 2-[(3s)-1-[5-[cyclohexyl(cyclopropylmethyl)carbamoyl]-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N(C1CCCCC1)CC1CC1 ZMLDBFQNSHTHBA-FQEVSTJZSA-N 0.000 claims 1
- AROMIVMFUAPFKU-SFHVURJKSA-N 2-[(3s)-1-[5-[cyclohexyl(ethyl)carbamoyl]-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N(CC)C1CCCCC1 AROMIVMFUAPFKU-SFHVURJKSA-N 0.000 claims 1
- SIRPPHOMDWANGK-INIZCTEOSA-N 2-[(3s)-1-[5-[methyl(oxan-4-yl)carbamoyl]-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N(C)C1CCOCC1 SIRPPHOMDWANGK-INIZCTEOSA-N 0.000 claims 1
- UMIQWAMCDLPJGV-FQEVSTJZSA-N 2-[(3s)-1-[6-[2-(4-chlorophenyl)ethylamino]-5-(cyclohexylcarbamoyl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1NCCC=2C=CC(Cl)=CC=2)=CC=C1C(=O)NC1CCCCC1 UMIQWAMCDLPJGV-FQEVSTJZSA-N 0.000 claims 1
- KVTZEZSPIHYJTE-QFIPXVFZSA-N 2-[(3s)-1-[6-[4-(benzenesulfonyl)piperazin-1-yl]-5-(cyclohexylcarbamoyl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1N2CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)=CC=C1C(=O)NC1CCCCC1 KVTZEZSPIHYJTE-QFIPXVFZSA-N 0.000 claims 1
- XROHBHIHWGAZJM-ZQRQZVKFSA-N 2-[(3s)-1-[6-cyclopentylsulfanyl-5-(3-pyridin-3-ylpyrrolidine-1-carbonyl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound C1[C@H](CC(=O)O)CCCN1C(N=C1SC2CCCC2)=CC=C1C(=O)N1CC(C=2C=NC=CC=2)CC1 XROHBHIHWGAZJM-ZQRQZVKFSA-N 0.000 claims 1
- KSFBJDKGSCPVAM-ZENAZSQFSA-N 2-[(3s)-1-[6-propylsulfanyl-5-(3-pyrazin-2-ylpyrrolidine-1-carbonyl)pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N(C1)CCC1C1=CN=CC=N1 KSFBJDKGSCPVAM-ZENAZSQFSA-N 0.000 claims 1
- SNJPVMVDQAXZMA-VYRBHSGPSA-N 2-[(3s)-1-[6-propylsulfanyl-5-[3-(trifluoromethyl)piperidine-1-carbonyl]pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N1CCCC(C(F)(F)F)C1 SNJPVMVDQAXZMA-VYRBHSGPSA-N 0.000 claims 1
- WLBGMTJZNWHPLM-OYKVQYDMSA-N 2-[(3s)-1-[6-propylsulfanyl-5-[3-[2-(trifluoromethyl)phenyl]pyrrolidine-1-carbonyl]pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N(C1)CCC1C1=CC=CC=C1C(F)(F)F WLBGMTJZNWHPLM-OYKVQYDMSA-N 0.000 claims 1
- ZEZQAIPFKAGRCU-HNNXBMFYSA-N 2-[(3s)-1-[6-propylsulfanyl-5-[4-(trifluoromethyl)piperidine-1-carbonyl]pyridin-2-yl]piperidin-3-yl]acetic acid Chemical compound CCCSC1=NC(N2C[C@H](CC(O)=O)CCC2)=CC=C1C(=O)N1CCC(C(F)(F)F)CC1 ZEZQAIPFKAGRCU-HNNXBMFYSA-N 0.000 claims 1
- ILMRIXNJBCQUJT-SFVHDIHTSA-N 2-[1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-4-yl]propanoic acid;(2s)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]pyrrolidine-2-carboxylic acid Chemical compound CCCSC1=NC(N2[C@@H](CCC2)C(O)=O)=CC=C1C(=O)NC1CCCCC1.CCCSC1=NC(N2CCC(CC2)C(C)C(O)=O)=CC=C1C(=O)NC1CCCCC1 ILMRIXNJBCQUJT-SFVHDIHTSA-N 0.000 claims 1
- DSKZCZYYGSJDHV-UHFFFAOYSA-N 2-[3-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]oxyphenyl]acetic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1OC1=CC=CC(CC(O)=O)=C1 DSKZCZYYGSJDHV-UHFFFAOYSA-N 0.000 claims 1
- ANODRYWADGDDLM-UHFFFAOYSA-N 2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]oxyphenoxy]acetic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1OC1=CC=C(OCC(O)=O)C=C1 ANODRYWADGDDLM-UHFFFAOYSA-N 0.000 claims 1
- QMJHGNGJQQDHLD-UHFFFAOYSA-N 2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]oxyphenyl]acetic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1OC1=CC=C(CC(O)=O)C=C1 QMJHGNGJQQDHLD-UHFFFAOYSA-N 0.000 claims 1
- HJRLXHFWMKEEIN-UHFFFAOYSA-N 2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]oxyphenyl]propanoic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1OC1=CC=C(C(C)C(O)=O)C=C1 HJRLXHFWMKEEIN-UHFFFAOYSA-N 0.000 claims 1
- LDPRXTKVDRGIMT-UHFFFAOYSA-N 2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperazin-1-yl]acetic acid Chemical compound CCCSC1=NC(N2CCN(CC(O)=O)CC2)=CC=C1C(=O)NC1CCCCC1 LDPRXTKVDRGIMT-UHFFFAOYSA-N 0.000 claims 1
- HUEDKGNPZYCQSB-UHFFFAOYSA-N 2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]sulfanylphenoxy]acetic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1SC1=CC=C(OCC(O)=O)C=C1 HUEDKGNPZYCQSB-UHFFFAOYSA-N 0.000 claims 1
- NOQVXLJWLRHUOL-UHFFFAOYSA-N 3-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]oxyphenyl]propanoic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1OC1=CC=C(CCC(O)=O)C=C1 NOQVXLJWLRHUOL-UHFFFAOYSA-N 0.000 claims 1
- XXYYNULUDPMDMY-UHFFFAOYSA-N 3-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]oxybenzoic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1OC1=CC=CC(C(O)=O)=C1 XXYYNULUDPMDMY-UHFFFAOYSA-N 0.000 claims 1
- SWEVLFSXNGUATR-UHFFFAOYSA-N 3-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]sulfanylbenzoic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1SC1=CC=CC(C(O)=O)=C1 SWEVLFSXNGUATR-UHFFFAOYSA-N 0.000 claims 1
- XEQUUHQPCQSWLQ-UHFFFAOYSA-N 4-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]oxybenzoic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1OC1=CC=C(C(O)=O)C=C1 XEQUUHQPCQSWLQ-UHFFFAOYSA-N 0.000 claims 1
- KAPYWLQJFUNOPV-UHFFFAOYSA-N 4-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]oxycyclohexane-1-carboxylic acid;1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidine-2-carboxylic acid Chemical compound CCCSC1=NC(N2C(CCCC2)C(O)=O)=CC=C1C(=O)NC1CCCCC1.C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1OC1CCC(C(O)=O)CC1 KAPYWLQJFUNOPV-UHFFFAOYSA-N 0.000 claims 1
- COPDWTHUTCKCJS-UHFFFAOYSA-N 4-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]sulfanylbenzoic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1SC1=CC=C(C(O)=O)C=C1 COPDWTHUTCKCJS-UHFFFAOYSA-N 0.000 claims 1
- WMUJIUMSLWYBGC-UHFFFAOYSA-N 4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]amino]cyclohexane-1-carboxylic acid;1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-4-propan-2-ylpiperidine-4-carboxylic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1NC1CCC(C(O)=O)CC1.CCCSC1=NC(N2CCC(CC2)(C(C)C)C(O)=O)=CC=C1C(=O)NC1CCCCC1 WMUJIUMSLWYBGC-UHFFFAOYSA-N 0.000 claims 1
- LNJRBNUEVZIFCD-UHFFFAOYSA-N 4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]methylamino]cyclohexane-1-carboxylic acid Chemical compound C=1C=C(C(=O)NC2CCCCC2)C(SCCC)=NC=1CNC1CCC(C(O)=O)CC1 LNJRBNUEVZIFCD-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- LDMKQJMSVUFGOC-NRYUZRROSA-N C1(CCCCC1)N(C(=O)C=1C=CC(=NC1N(CCC)C)N1C[C@@H](CCC1)CC(=O)O)C.C1(CCCCC1)N(C(=O)C=1C=CC(=NC1NCCC)N1C[C@@H](CCC1)CC(=O)O)C Chemical compound C1(CCCCC1)N(C(=O)C=1C=CC(=NC1N(CCC)C)N1C[C@@H](CCC1)CC(=O)O)C.C1(CCCCC1)N(C(=O)C=1C=CC(=NC1NCCC)N1C[C@@H](CCC1)CC(=O)O)C LDMKQJMSVUFGOC-NRYUZRROSA-N 0.000 claims 1
- YJYWFIRRUMBGLN-QAOGLABXSA-N C1(CCCCC1)N(C(=O)C=1C=CC(=NC1SCCC)N1C[C@@H](CCC1)CC(=O)O)C.C1(CCCCC1)N(C(=O)C=1C=CC(=NC1SCCC)N1C[C@H](CCC1)CC(=O)O)C Chemical compound C1(CCCCC1)N(C(=O)C=1C=CC(=NC1SCCC)N1C[C@@H](CCC1)CC(=O)O)C.C1(CCCCC1)N(C(=O)C=1C=CC(=NC1SCCC)N1C[C@H](CCC1)CC(=O)O)C YJYWFIRRUMBGLN-QAOGLABXSA-N 0.000 claims 1
- MZOCCLLCCUPGCA-DWBCTQMISA-N C1(CCCCC1)NC(=O)C=1C=CC(=NC1N1CCCCC1)N1C[C@@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1OCCC)N1C[C@@H](CCC1)CC(=O)O Chemical compound C1(CCCCC1)NC(=O)C=1C=CC(=NC1N1CCCCC1)N1C[C@@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1OCCC)N1C[C@@H](CCC1)CC(=O)O MZOCCLLCCUPGCA-DWBCTQMISA-N 0.000 claims 1
- YGWYCCITSVHIFX-USPCTWCJSA-N C1(CCCCC1)NC(=O)C=1C=CC(=NC1N1CCOCC1)N1C[C@@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1N1CCCC1)N1C[C@@H](CCC1)CC(=O)O Chemical compound C1(CCCCC1)NC(=O)C=1C=CC(=NC1N1CCOCC1)N1C[C@@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1N1CCCC1)N1C[C@@H](CCC1)CC(=O)O YGWYCCITSVHIFX-USPCTWCJSA-N 0.000 claims 1
- FTFLWBUBWCZFMF-QUJONECCSA-N C1(CCCCC1)NC(=O)C=1C=CC(=NC1OC)N1C[C@@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1OCCC=1C=NC=CC1)N1C[C@@H](CCC1)CC(=O)O Chemical compound C1(CCCCC1)NC(=O)C=1C=CC(=NC1OC)N1C[C@@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1OCCC=1C=NC=CC1)N1C[C@@H](CCC1)CC(=O)O FTFLWBUBWCZFMF-QUJONECCSA-N 0.000 claims 1
- IIEQBMNCIFBDGK-KLTJRSTASA-N C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCC1)N1C[C@@H](CC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCC1)N1C[C@@H](CCC1)CC(=O)O Chemical compound C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCC1)N1C[C@@H](CC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCC1)N1C[C@@H](CCC1)CC(=O)O IIEQBMNCIFBDGK-KLTJRSTASA-N 0.000 claims 1
- IIEQBMNCIFBDGK-IWOKJYGASA-N C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCC1)N1C[C@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCC1)N1C[C@H](CC1)CC(=O)O Chemical compound C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCC1)N1C[C@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCC1)N1C[C@H](CC1)CC(=O)O IIEQBMNCIFBDGK-IWOKJYGASA-N 0.000 claims 1
- PCWJPMGRRJIQHJ-BXONKRMDSA-N C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCCC1)N1C[C@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCCC1)N1C[C@H](CC1)CC(=O)O Chemical compound C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCCC1)N1C[C@H](CCC1)CC(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SC1CCCCC1)N1C[C@H](CC1)CC(=O)O PCWJPMGRRJIQHJ-BXONKRMDSA-N 0.000 claims 1
- HVDBQQNZYNAOGA-UHFFFAOYSA-N C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(CCC1)C1(CCC1)C(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(C1)OCC(=O)O Chemical compound C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(CCC1)C1(CCC1)C(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(C1)OCC(=O)O HVDBQQNZYNAOGA-UHFFFAOYSA-N 0.000 claims 1
- UFQMQWXJHKRUQE-UHFFFAOYSA-N C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(CCC1)OC(C(=O)O)C.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(CC1)OCC(=O)O Chemical compound C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(CCC1)OC(C(=O)O)C.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(CC1)OCC(=O)O UFQMQWXJHKRUQE-UHFFFAOYSA-N 0.000 claims 1
- JXZLBXFFSTWUHG-UHFFFAOYSA-N C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(OCC1)C(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CCC(CC1)C1(CC1)C(=O)O Chemical compound C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CC(OCC1)C(=O)O.C1(CCCCC1)NC(=O)C=1C=CC(=NC1SCCC)N1CCC(CC1)C1(CC1)C(=O)O JXZLBXFFSTWUHG-UHFFFAOYSA-N 0.000 claims 1
- AISBYVUOHSDWHC-UIRBOTONSA-N C12(CC3CC(CC(C1)C3)C2)NC(=O)C=2C=CC(=NC2C)N2C[C@@H](CCC2)CC(=O)O.C2(CCCCC2)NC(=O)C=2C=CC(=NC2C)N2C[C@@H](CCC2)CC(=O)O Chemical compound C12(CC3CC(CC(C1)C3)C2)NC(=O)C=2C=CC(=NC2C)N2C[C@@H](CCC2)CC(=O)O.C2(CCCCC2)NC(=O)C=2C=CC(=NC2C)N2C[C@@H](CCC2)CC(=O)O AISBYVUOHSDWHC-UIRBOTONSA-N 0.000 claims 1
- IXZFNFVLPIRJIE-AAQIHDJVSA-N C12C(C3CC(CC(C1)C3)C2)NC(=O)C=2C=CC(=NC2SCCC)N2CC(OCC2)C(=O)O.C23C(C1CC(CC(C2)C1)C3)NC(=O)C=3C=CC(=NC3SCCC)N3C[C@H](CC3)C(=O)O Chemical compound C12C(C3CC(CC(C1)C3)C2)NC(=O)C=2C=CC(=NC2SCCC)N2CC(OCC2)C(=O)O.C23C(C1CC(CC(C2)C1)C3)NC(=O)C=3C=CC(=NC3SCCC)N3C[C@H](CC3)C(=O)O IXZFNFVLPIRJIE-AAQIHDJVSA-N 0.000 claims 1
- FENAVTGQAHZRRC-RNMMSVKLSA-N C12C(C3CC(CC(C1)C3)C2)NC(=O)C=2C=CC(=NC2SCCC)N2C[C@@H](CC2)OCC(=O)O.C23C(C1CC(CC(C2)C1)C3)NC(=O)C=3C=CC(=NC3SCCC)N3C[C@H](CC3)OCC(=O)O Chemical compound C12C(C3CC(CC(C1)C3)C2)NC(=O)C=2C=CC(=NC2SCCC)N2C[C@@H](CC2)OCC(=O)O.C23C(C1CC(CC(C2)C1)C3)NC(=O)C=3C=CC(=NC3SCCC)N3C[C@H](CC3)OCC(=O)O FENAVTGQAHZRRC-RNMMSVKLSA-N 0.000 claims 1
- WSQMPDOQHOWQBR-CNPYRHABSA-N C12C(C3CC(CC(C1)C3)C2)NC(=O)C=2C=CC(=NC2SCCC)N2C[C@@H](CCC2)CC(=O)O.C2(CCCCC2)NC(=O)C=2C=CC(=NC2SC2CCCC2)N2CC(CCC2)C2(CC2)C(=O)O Chemical compound C12C(C3CC(CC(C1)C3)C2)NC(=O)C=2C=CC(=NC2SCCC)N2C[C@@H](CCC2)CC(=O)O.C2(CCCCC2)NC(=O)C=2C=CC(=NC2SC2CCCC2)N2CC(CCC2)C2(CC2)C(=O)O WSQMPDOQHOWQBR-CNPYRHABSA-N 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- VKVXVPNFWYSSNF-XHFVKCHCSA-N N1(CCCCC1)C(=O)C=1C=CC(=NC1SCCC)N1C[C@@H](CCC1)CC(=O)O.C(CC)SC1=C(C=CC(=N1)N1C[C@@H](CCC1)CC(=O)O)C(=O)N1CC(CC1)C1=NC=CC=C1 Chemical compound N1(CCCCC1)C(=O)C=1C=CC(=NC1SCCC)N1C[C@@H](CCC1)CC(=O)O.C(CC)SC1=C(C=CC(=N1)N1C[C@@H](CCC1)CC(=O)O)C(=O)N1CC(CC1)C1=NC=CC=C1 VKVXVPNFWYSSNF-XHFVKCHCSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N alpha-isobutyric acid Natural products CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Spoj formule (1): naznačen time da: Q je jednostruka veza, -O-, -S- ili -N(R15)- pri čemu R15 je vodik, C1-3alkil ili C2-3alkanoil ili R15 i R1 zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani zasićeni prsten; R1 je C1-6alkil, C2-6alkenil, C2-6alkinil, C3-7cikloalkil, C3-7cikloalkilC1-3alkil, C3-7cikloalkilC2-3alkenil, C3-7cikloalkilC2-3alkinil, fenil, fenilC1-3alkil, heteroaril, heteroarilC1-3alkil, heterociklil, ili heterociklilC1-3alkil [svaki od kojih je opcionalno supstituiran sa 1, 2 ili 3 supstituenta nezavisno odabranih od C1-3alkil, hidroksi, halo, okso, cijano, trifluorometil, C1-3alkoksi, karboksiC1-3alkil, C1-3alkilS(O)n-(pri čemu n je 0, 1, 2 ili 3), R5CON(R5')-, (R5')(R5')NC(O)-, R5'C(O)-, R5'OC(O)- i (R5')(R5')NSO2- (pri čemu R5 je C1-3alkil opcionalno supstituiran sa 1, 2 ili 3 supstituenta nezavisno odabranih od hidroksil, halo i cijano; iR5' i R5" su nezavisno odabrani od vodika i C1-3alkila opcionalno supstituirani sa 1, 2 ili 3 supstituenta nezavisno odabranih od hidroksil, halo, C1-3alkoksi, karboksi i cijano ili R5' i R5" zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani zasićeni prsten)] i opcijskih supstituenata za heterociklil i heterociklilna skupina u heterociklilC1-3alkilu su dodatno odabrani od R21, R21CO- R21S(O)k (pri čemu k je 0, 1 ili 2) i R21CH2OC(O)- pri čemu R21 je fenil opcionalno supstituiran sa 1 ili 2 supstituenta nezavisno odabranih od halo, hidroksi, cijano i trifluorometil; ilikada Q je veza R1 može također biti vodik, pri čemu heterociklil je 4-7 zasićeni, monociklički prsten koji ima 1-3 heteroatoma prstena odabrana od dušika, kisika i sumpora; R2 je odabran od C3-7cikloalkil(CH2)m-, i C6-12policikloalkil(CH2)m- (pri čemu prsteni cikloalkila i policikloalkila opcijski sadrže 1 ili 2 atoma prstena nezavisno odabranih od dušika, kisika i sumpora; m je 0, 1 ili 2 i prsteni su opcionalno supstituirani sa 1, 2 ili 3 supstituenta nezavisno odabranih od R6);R3 je odabran od vodika, C1-4alkila, C3-5cikloalkila i C3-5cikloalkilmetila; R2 i R3 zajedno sa atomom dušika na koji su spojeni tvore zasićeni mono, biciklički ili premošteni sustav prstena koji opcijski sadrži 1 ili 2 dodatna heteroatoma prstena odabranih od dušika, kisika i sumpora i koji su opcijski spojeni na zasićeni, djelomično zasićeni ili nezasićeni monociklički prsten pri čemu je sustav rezultirajućeg prstena opcionalno supstituiran sa 1, 2, ili 3 supstituenta nezavisno odabranih od R7;R4 je nezavisno odabran od halo, C1-2alkila, cijano, C1-2alkoksi, i trifluorometila; R6 i R7 su nezavisno odabrani od hidroksila, halo, okso, karboksi, cijano, trifluorometila, R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9")NC(O)-, (R9')(R9")N-, R9S(O)a- pri čemu a je 0 do 2, R9'OC(O)-, (R9')(R9")NSO2-, R9SO2N(R9")-, (R9')(R9")NC(O)N(R9'")-, fenil i heteroaril [pri čemu su fenilne i heteroarilne skupine opcijski spojene na fenil, heteroaril ili na zasićeni ili djelomično-zasićeni 5- ili 6-člani prsten koji opcijski sadrži 1, 2 ili 3 heteroa
Claims (16)
1. Spoj formule (1):
[image]
naznačen time da:
Q je jednostruka veza, -O-, -S- ili -N(R15)- pri čemu R15 je vodik, C1-3alkil ili C2-3alkanoil ili R15 i R1 zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani zasićeni prsten;
R1 je C1-6alkil, C2-6alkenil, C2-6alkinil, C3-7cikloalkil, C3-7cikloalkilC1-3alkil,
C3-7cikloalkilC2-3alkenil, C3-7cikloalkilC2-3alkinil, fenil, fenilC1-3alkil, heteroaril, heteroarilC1-3alkil, heterociklil, ili heterociklilC1-3alkil [svaki od kojih je opcionalno supstituiran sa 1, 2 ili 3 supstituenta nezavisno odabranih od C1-3alkil, hidroksi, halo, okso, cijano, trifluorometil, C1-3alkoksi, karboksiC1-3alkil, C1-3alkilS(O)n-(pri čemu n je 0, 1, 2 ili 3), R5CON(R5')-, (R5')(R5')NC(O)-, R5'C(O)-, R5'OC(O)- i (R5')(R5')NSO2- (pri čemu R5 je C1-3alkil opcionalno supstituiran sa 1, 2 ili 3 supstituenta nezavisno odabranih od hidroksil, halo i cijano; i
R5' i R5" su nezavisno odabrani od vodika i C1-3alkila opcionalno supstituirani sa 1, 2 ili 3 supstituenta nezavisno odabranih od hidroksil, halo, C1-3alkoksi, karboksi i cijano ili R5' i R5" zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani zasićeni prsten)] i opcijskih supstituenata za heterociklil i heterociklilna skupina u heterociklilC1-3alkilu su dodatno odabrani od R21, R21CO- R21S(O)k (pri čemu k je 0, 1 ili 2) i R21CH2OC(O)- pri čemu R21 je fenil opcionalno supstituiran sa 1 ili 2 supstituenta nezavisno odabranih od halo, hidroksi, cijano i trifluorometil; ili
kada Q je veza R1 može također biti vodik, pri čemu heterociklil je 4-7 zasićeni, monociklički prsten koji ima 1-3 heteroatoma prstena odabrana od dušika, kisika i sumpora;
R2 je odabran od C3-7cikloalkil(CH2)m-, i C6-12policikloalkil(CH2)m- (pri čemu prsteni cikloalkila i policikloalkila opcijski sadrže 1 ili 2 atoma prstena nezavisno odabranih od dušika, kisika i sumpora; m je 0, 1 ili 2 i prsteni su opcionalno supstituirani sa 1, 2 ili 3 supstituenta nezavisno odabranih od R6);
R3 je odabran od vodika, C1-4alkila, C3-5cikloalkila i C3-5cikloalkilmetila;
R2 i R3 zajedno sa atomom dušika na koji su spojeni tvore zasićeni mono, biciklički ili premošteni sustav prstena koji opcijski sadrži 1 ili 2 dodatna heteroatoma prstena odabranih od dušika, kisika i sumpora i koji su opcijski spojeni na zasićeni, djelomično zasićeni ili nezasićeni monociklički prsten pri čemu je sustav rezultirajućeg prstena opcionalno supstituiran sa 1, 2, ili 3 supstituenta nezavisno odabranih od R7;
R4 je nezavisno odabran od halo, C1-2alkila, cijano, C1-2alkoksi, i trifluorometila;
R6 i R7 su nezavisno odabrani od hidroksila, halo, okso, karboksi, cijano, trifluorometila, R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9")NC(O)-, (R9')(R9")N-, R9S(O)a- pri čemu a je 0 do 2, R9'OC(O)-, (R9')(R9")NSO2-, R9SO2N(R9")-, (R9')(R9")NC(O)N(R9'")-, fenil i heteroaril [pri čemu su fenilne i heteroarilne skupine opcijski spojene na fenil, heteroaril ili na zasićeni ili djelomično-zasićeni 5- ili 6-člani prsten koji opcijski sadrži 1, 2 ili 3 heteroatoma nezavisno odabranih od dušika, kisika i sumpora i rezultirajući sustav prstena je opcionalno supstituiran sa 1, 2 ili 3 supstituenta nezavisno odabranih od C1-4alkila, hidroksila, cijano, trifluorometila, trifluoromoksi, halo, C1-4alkoksi, C1-4alkoksiC1-4alkila, C1-4alkoksiC1-4alkila, amino, N-C1-4alkilamino, diN,N-(C1-4alkil)amino, N-C1-4alkilkarbamoila, di-N,N-(C1-4alkil)karbamoila, C1-4alkilS(O)r-, C1-4alkilS(O)rC1-4alkila (pri čemu r je 0, 1 i 2)]; pri čemu heteroaril, ukoliko nije drugačije naznačeno, je u cijelosti nezasićeni, monociklički prsten koji sadrži 5 ili 6 atoma od kojih barem 1, 2 ili 3 atom prsten su nezavisno odabrani od dušika, sumpora ili kisika, koji mogu, ukoliko nije drugačije naznačeno, biti ugljikova-veza R9 je nezavisno C1-3alkil opcionalno supstituiran sa 1, 2 ili 3 supstituenta nezavisno odabrana od hidroksil, halo, C1-4alkoksi, karboksi i cijano;
R9', R9" i R9'" su nezavisno odabrani od vodika i C1-3alkila opcionalno supstituirani sa hidroksilom, halo, C1-4alkoksi, karboksi ili cijano);
p je 0, 1 ili 2;
svaki X je -O(CH2)q-, -S(CH2)q- ili -N(R12)(CH2)q- pri čemu R12 je vodik, C1-3alkil ili
C1-3alkanoil i q je 0 ili 1; i
Y je:
1) C3-7cikloalkdiil prsten, fenilenski prsten, adamantdiilna skupina, 5-7 člani zasićeni heterociklički prsten (povezan sa atomom prstena ugljika) koji sadrži 1 ili 2 prstena heteroatoma odabranih od dušika, kisika i sumpora, ili -[C(Rx)(Ry)]v-(pri čemu Rx i Ry su nezavisno odabrani od vodika, C1-3alkila, C1-3alkoksi i hidroksila ili Rx i Ry zajedno sa atomom ugljika na koji su povezani tvore C3-7cikloalkdiilni prsten i v je 1, 2, 3, 4 ili 5) i kada je v veće od 1 -[C(Rx)(Ry)]v- skupina može po potrebi biti prekinuta sa -O-, -S- ili -N(R20)- skupinom pri čemu R20 je vodik ili C1-3alkil; ili
2) -X-Y- zajedno predstavlja skupinu formule:
[image]
pri čemu:
prsten A je vezan na piridinsku skupinu i -(Z)t[C(R13)(R14)]e- je vezan na karboksilnu skupinu; i
A je 4-7 člani mono-, bi- ili spiro sustav heterocikličkog prstena koji uključuje piperazinil, piperidinil i morfolinil koji sadrži atom prstena dušika putem kojeg je povezan na piridinski prsten i dodatno po potrebi jedan drugi prsten heteroatoma odabranih od dušika, kisika i sumpora;
Z je -O-, -S- ili -N(R16)- pri čemu R16 je vodik, C1-3alkil ili C1-3alkanoil;
t je 0 ili 1 pod uvjetom da kada s je 0 tada t je 0;
R10 je nezavisno odabran od C1-3alkila, C2-3alkenila, C2-3alkinila, hidroksi, halo, okso, cijano, trifluorometila, C1-3alkoksi, C1-3alkilS(O)n- (pri čemu n je 0, 1, 2 ili 3), R11CON(R11'), (R11')(R11")NC(O)-, R11'OC(O)- i (R11')(R11")NSO2- (pri čemu R11 je C1-3alkil opcionalno supstituiran sa hidroksilom, halo ili cijano; i
R11' i R11" su nezavisno odabrani od vodika i C1-3alkila opcionalno supstituirani sa hidroksilom, halo, C1-3alkoksi, karboksi ili cijano) ili R11' i R11" zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani prsten;
u je 0, 1 ili 2;
R13 i R14 su nezavisno odabrani od vodika i C1-3alkila ili R13 i R14 mogu zajedno sa atomom ugljika na koji su povezani tvoriti C3-7cikloalkilni prsten; i
s je 0, 1 ili 2;
ili a farmaceutski prihvatljiva sol ili njihov in vivo hidrolizirajući ester;
pod uvjetom da spoj nije:
{(3S)-1-[5-(adamantan-1-ilkarbamoil)piridin-2-il]piperidin-3-il}octena kiselina; ili
{(3S)-1-[5-(cikloheksilkarbamoil)-6-(piperazin-1-il)piridin-2-il]piperidin-3-il}octena kiselina;
ili farmaceutski prihvatljiva sol ili njihov in vivo hidrolizirajući ester.
2. Spoj prema zahtjevu 1 naznačen time da:
Q je O, S ili jednostruka veza i R1 je C1-6alkil, C2-6alkenil, C2-5alkinil, C3-7cikloalkil,
C3-7cikloolkilC1-3alkil, C3-7cikloalkilC2-3alkenil ili C3-7cikloalkilC2-3alkinil, [svaki od kojih je opcionalno supstituiran sa 1, 2 ili 3 supstituenta nezavisno odabranih od
C1-3alkila, hidroksi, halo, okso, cijano, trifluorometila, C1-3alkoksi, C1-3alkilS(O)n-(pri čemu n je 0, 1, 2 ili 3), R5CON(R5')-, (R5)(R5")NC(O)-, R5'OC(O)- i (R5)(R5")NSO2- (pri čemu R5 je C1-3alkil opcionalno supstituiran sa 1, 2 ili 3 supstituenta nezavisno odabrana od hidroksila, halo i cijano; i R5' i R5" su nezavisno odabrani od vodika i C1-3alkila opcionalno supstituirani sa 1, 2 ili 3 supstituenta nezavisno hidroksila, halo, C1-3alkoksi, karboksi i cijano ili R5' i R5' zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani zasićeni prsten)].
3. Spoj prema zahtjevu 1 naznačen time da Q je -S- i R1 je C1-6alkil, C3-7cikloalkil ili C3-7cikloalkilC1-3alkil.
4. Spoj prema bilo kojem od zahtjeva 1 do 3 naznačen time da p je 0.
5. Spoj prema bilo kojem od zahtjeva 1 do 4 naznačen time da R2 je odabran od C3-7cikloalkil(CH2)m-, i C6-12policikloalkil(CH2)m- (pri čemu m je 0, 1 ili 2 i prsteni su opcionalno supstituirani sa 1 ili 2 supstituenta nezavisno odabranih od R6, i R6 je nezavisno odabran od hidroksila, halo i trifluorometila).
6. Spoj prema bilo kojem od zahtjeva 1 do 5 naznačen time da R3 je vodik.
7. Spoj prema bilo kojem od zahtjeva 1 do 4 naznačen time da R2 i R3 zajedno sa atomom dušika na koji su spojeni tvore zasićeni 5 ili 6-člani mono, sustav prstena koji opcijski sadrži 1 dodatni prsten heteroatoma odabranih od dušika, kisika i sumpora, te je opcionalno supstituiran sa 1 ili 2 supstituenta nezavisno odabranih od R7 pri čemu je R7 odabran od hidroksi, halo i trifluorometila.
8. Spoj prema bilo kojem od zahtjeva 1 to 7 naznačen time da X je -O-, -S- ili-N(R12)- pri čemu R12 je vodik, C1-3alkil ili C1-3alkanoil i Y je C3-7cikloalkdiilni prsten ili 5-7 člani zasićeni heterociklički prsten (povezan sa atomom prstena ugljika) koji sadrži 1 ili 2 prstena heteroatoma odabranih od dušika, kisika i sumpora.
9. Spoj prema bilo kojem od zahtjeva 1 to 7 naznačen time da -X-Y- zajedno predstavljaju skupinu formule:
[image]
pri čemu:
prsten A je vezan na piridinsku skupinu i -[C(R13)(R14)]s- je vezan na karboksilnu skupinu; i
A je 4-7 člani mono-, bi- ili spiro heterociklički sustav prstena koji sadrži atom prstena dušika pomoću kojeg je povezan ns piridinski prsten i dodatno po potrebi jedan drugi prsten heteroatoma odabranih od dušika, kisika i sumpora;
R10 je nezavisno odabran od C1-3alkila, hidroksi, halo i trifluorometila;
u je 0, ili 1;
R13 i R14 su nezavisno odabrani od vodika i C1-3alkila ili R13 i R14 mogu zajedno sa atomom ugljika na koji su povezani tvoriti C3-7cikloalkilni prsten; i
s je 0, 1 ili 2.
10. Spoj prema zahtjevu 1, naznačen time da je:
2-[(3R)-1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]piperidin-3-karboksilna kiselina
1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]piperidin-4-karboksilna kiselina
2-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-4-piperidil]octena kiselina
2-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidine-3-karboksilna kiselina
2-[(3S)-1-[5-(ciklooheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]piperazin-1-il]octena kiselina
(3R,5S)-4-[[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]amino]adamantan-1-karboksilna kiselina
(3R, 5S)-4-[[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]amino]adamantan-1-karboksilna kiselina
4-[[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-metil-amino]cikloheksan-1-karboksilna kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
3-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]oksibenzojeva kiselina
3-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]sulfanilbenzojeva kiselina
4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]sulfanilbenzojeva kiselina
4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]oksibenzojeva kiselina
2-[4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]oksifenil]octena kiselina
3-[4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]oksifenil]propanska kiselina
2-[4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]sulfanilfenoksi]octena kiselina
2-[4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]oksifenoksi]octena kiselina
2-[4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]oksifenil]propanska kiselina
2-[4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]sulfanilfenil]octena kiselina
2-[3-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]oksifenil]octena kiselina
2-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]sulfanilbenzojeva kiselina
4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]oksicikloheksan-1-karboksilna kiselina
1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]piperidin-2-karboksilna kiselina
(2S)-1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidine-2-karboksilna kiselina
2-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-4-piperidil]propanska kiselina
4-[[[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]amino]metil]cikloheksan-1-karboksilna kiselina
3-[[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]amino]propanska kiselina
1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]azepan-4-karboksilna kiselina
1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-4-metil-piperidin-4-karboksilna kiselina
(1S,5R)-3-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-azabiciklo[3.1.0]heksan-6-karboksilna kiselina
4-[[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]amino]cikloheksan-1-karboksilna kiselina
1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-4-propan-2-il-piperidin-4-karboksilna kiselina
1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-metil-piperidin-4-karboksilna kiselina
2-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]-2-metil-propanska kiselina
2-[(3R)-1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
3-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]propanskakiselina
2-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]azetidin-3-il]oksioctena kiselina
1-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]ciklobutan-1-karboksilna kiselina
1-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]ciklopropan-1-karboksilna kiselina
2-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidin-3-il]oksioctena kiselina
2-[[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]oksi]propanska kiselina
2-[[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]oksi]-2-metil-propanska kiselina
2-[[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3piperidil]oksi]octena kiselina
1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-metil-piperidin-3-karboksilna kiselina
2-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-4-piperidil]-2-metil-propanska kiselina
1-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-4-piperidil]ciklobutan-1-karboksilna kiselina
1-[1-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]-4-piperidil]ciklopropan-1-karboksilna kiselina
4-[5-(cikloheksilkarbamoil)-6-propilsulfanil-piridin-2-il]morfoline-2-karboksilna kiselina
2-[(3R)-1-[5-(cikloheksilkarbamoil)-6-cikloheksilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
2-[(3R)-1-[5-(cikloheksilkarbamoil)-6-cikloheksilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-ciklopentilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-ciklopentilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
2-[(3R)-1-[5-(cikloheksilkarbamoil)-6-ciklopentilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
2-[(3R)-1-[5-(cikloheksilkarbamoil)-6-ciklopentilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
1-[1-[5-(cikloheksilkarbamoil)-6-ciklopentilsulfanil-piridin-2-il]-3-piperidil]ciklopropan-1-karboksilna kiselina
2-[(3S)-1-[5-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidin-3-il]oksioctena kiselina
2-[(3R)-1-[5-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidin-3-il]oksioctena kiselina
2-[(3S)-1-[5-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
(3R)-1-[5-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidine-3-karboksilna kiselina
2-[(3R)-1-[6-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
(2S)-1-[5-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidine-2-karboksilna kiselina
(1S,5R)-3-[5-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]-3-azabiciklo[3.1.0]heksan-6-karboksilna kiselina
(3S)-1-[5-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]pirolidine-3-karboksilna kiselina
4-[5-(2-adamantilkarbamoil)-6-propilsulfanil-piridin-2-il]morfoline-2-karboksilna kiselina
2-[(3S)-1-[5-(2-adamantilkarbamoil)-6-ciklopentilsulfanil-piridin-2-il]pirolidin-3-il]oksioctena kiselina
2-[(3R)-1-[5-(2-adamantilkarbamoil)-6-ciklopentilsulfanil-piridin-2-il]pirolidin-3-il]oksioctena kiselina
2-[(3S)-1-[5-(2-adamantilkarbamoil)-6-cikloheksilsulfanil-piridin-2-il]pirolidin-3-il]oksioctena kiselina
2-[(3R)-1-[5-(2-adamantilkarbamoil)-6-cikloheksilsulfanil-piridin-2-il]pirolidin-3-il]oksioctena kiselina
2-[(3R)-1-[5-(2-adamantilkarbamoil)-6-etilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
(3R)-1-[5-(2-adamantilkarbamoil)-6-etilsulfanil-piridin-2-il]pirolidine-3-karboksilna kiselina
(38)-1-[5-(2-adamantilkarbamoil)-6-etilsulfanil-piridin-2-il]pirolidine-3-karboksilna kiselina
(1S,5R)-3-[5-(2-adamantilkarbamoil)-6-etilsulfanil-piridin-2-il]-3-azabiciklo[3.1.0]heksan-6-karboksilna kiselina
2-[(3R)-1-[5-(2-adamantilkarbamoil)-6-metilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
(3R)-1-[5-(2-adamantilkarbamoil)-6-metilsulfanil-piridin-2-il]pirolidine-3-karboksilna kiselina
(1S,5R)-3-[5-(2-adamantilkarbamoil)-6-metilsulfanil-piridin-2-il]-3-azabiciklo[3.1.0]heksan-6-karboksilna kiselina
2-[(3S)-1-[5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]-6-propilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
4-[[[5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]-6-propilsulfanil-piridin-2-il]amino]metil]cikloheksan-1-karboksilna kiselina
4-[[5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]-6-propilsulfanil-piridin-2-il]amino]cikloheksan-1-karboksilna kiselina
4-[[5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]-6-propilsulfanil-piridin-2-il]amino]cikloheksan-1-karboksilna kiselina
2-1(3S)-1-[5-[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]piperidin-4-karboksilna kiselina
2-[(3R)-1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]-4-piperidil]octena kiselina
(1R,5S)-3-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]-3-azabiciklo[3.1.0]heksan-6-carbksilic kiselina
1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]-4-metil-piperidin-4-karboksilna kiselina
1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]pirolidine-3-karboksilna kiselina
2-[(3R)-1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
3-[1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]-3-piperidil]propanska kiselina
2-[1-[5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]-6-propilsulfanil-piridin-2-il]-3-piperidil]-2-metil-propanska kiselina
2-[(3S)-1-[6-ciklopentilsulfanil-5-[((2r, 5s)-5-hidroksi-2-adamantil)karbamoil]piridin-2-il]pirolidin-3-il]octena kiselina
2-[(3S)-1-[6-ciklopentilsulfanil-5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]piridin-2-il]-3-piperidil]octena kiselina
2-[(3R)-1-[6-ciklopentilsulfanil-5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]piridin-2-il]pirolidin-3-il]octena kiselina
(3R)-1-[6-ciklopentilsulfanil-5-[((2r5s)-5-hidroksi2-adamantil)karbamoil]piridin-2-il]pirolidine-3-karboksilna kiselina
(2S)-1-[6-ciklopentilsulfanil-5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]piridin-2-il]pirolidine-2-karboksilna kiselina
(1R,5S)-3-[6-ciklopentilsulfanil-5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]piridin-2-il]-3-azabiciklo[3.1.0]heksan-6-karboksilna kiselina
1-[6-ciklopentilsulfanil-5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]piridin-2-il]piperidin-4-karboksilna kiselina
2-[(3R)-1-[6-cikloheksilsulfanil-5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]piridin-2-il]pirolidin-3-il]octena kiselina
(2S)-1-[6-cikloheksilsulfanil-5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]piridin-2-il]pirolidine-2-karboksilna kiselina
(3R)-1-[6-cikloheksilsulfanil-5-[((2r,5s)-5-hidroksi-2-adamantil)camamoil]piridin-2-il]pirolidine-3-karboksilna kiselina
2-[(3S)-1-[6-cikloheksilsulfanil-5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-(3-metilbutilsulfanil)piridin-2-il]-3-piperidil]octena kiselina
(3R)-1-[5-[(2r,5s)-5-hidroksi-2-adamantil)karbamoil]-6-(3-metilbutilsulfanil)piridin-2-il]pirolidine-3-karboksilna kiselina
(1R,5S)-3-[5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]-6-(3-metilbutilsulfanil)piridin-2-il]-3-azabiciklo[3.1.0]heksan-6-karboksilna kiselina
2-[(3S)-1-[6-benzilsulfanil-5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]piridin-2-il]-3-piperidil]octena kiselina
2-[(3F)-1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-fenetilsulfanil-piriclin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]-6-propoksi-piridin-2-il]-3-piperidil]octena kiselina
2-[1-[5-[((2r,5s)-5-hidroksi-2-adamantil)karbamoil]-6-propoksi-piridin-2-il]-3-piperidil]-2-metil-propanska kiselina
(1R,5S,6r)-3-(6-(ciklopentilthio)-5-(3-(piridin-3-il)pirolidine-1-karbonil)piridin-2-il)-3-azabiciklo[3.1.0]heksan-6-karboksilna kiselina
(1S,5R)-3-[6-cikloheksilsulfanil-5-(3-piridin-3-ilpirolidine-1-karbonil)piridin-2-il]-3-azabiciklo[3.1.0]heksan-6-karboksilna kiselina
2-[(3S)-1-[6-propilsulfanil-5-(3-piridin-3-ilpirolidine-1-karbonil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-propilsulfanil-5-(3-piridin-2-ilpirolidine-1-karbonil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(piperidin-1-karbonil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-propilsulfanil-5-(3-pirazin-2-ilpirolidine-1-karbonil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(4,4-difluoropiperidin-1-karbonil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-propilsulfanil-5-[3-(trifluorometil)piperidin-1-karbonil]piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-propilsulfanil-5-[4-(trifluorometil)piperidin-1-karbonil]piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(4-karbamoilpiperidin-1-karbonil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksil-ciklopropil-karbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksil-(ciklopropilmetil)karbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksil-etil-karbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksil-propan-2-il-karbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-[(4-hidroksicikloheksil)karbamoil]-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-propilsulfanil-5-[3-[2-(trifluorometil)fenil]pirolidine-1-karbonil]piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-[((2r,5s)-5-metilsulfonil-2-adamantil)karbamoil]-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-ciklopentilsulfanil-5-(3-piridin-3-ilpirolidine-1-karbonil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3R)-1-[5-(cikloheksilkarbamoil)-6-fenetilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-fenetilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(2-piridin-3-iletilsulfanil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(2-pirazin-2-iletilsulfanil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-[2-(4-fluorofenil)ethoksi]piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(3-metilbutoksi)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(3-fenilpropoksi)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(2-piridin-3-ilethoksi)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-methoksi-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-propoksi-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(1-piperidil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-[2-(4-chlorofenil)etilamino]-5-(cikloheksilkarbamoil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-[3-(4-fluorofenil)pirolidin-1-il]piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(3,4-dihidro-1H-izokvinolin-2-il)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(3,4-dihidro-1H-izokvinolin-2-il)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(4-fenilpiperazin-1-il)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-[4-(4-fluorobenzoil)piperazin-1-il]piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-(4-acetilpiperazin-1-il)-5-(cikloheksilkarbamoil)piridin-2-il]-3-plperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(4-etilsulfonilpiperazin-1-il)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-[4-(benzensulfonil)piperazin-1-il]-5-(cikloheksilkarbamoil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(4-fenilmethoksikarbonilpiperazin-1-il)piridin-2-il]-3-piperidil]octena kiselina
2-[(SS)-1-[5-(cikloheksilkarbamoil)-6-propilamino-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(fenetilamino)piridin-2-il]-3-pipeddil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(metil-fenetil-amino)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-(metil-propil-amino)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-pirolidin-1-il-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-morfolin-4-il-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksil-metil-karbamoil)-6-propilamino-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksil-metil-karbamoil)-6-(metil-propil-amino)piridin-2-il]-3-piperidil]octena kiselina2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-metil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(1-adamantilkarbamoil)-6-metil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(2-adamantilkarbamoil)-6-metil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(2-adamantilkarbamoil)-6-butil-piridin-2-il]-3-piperidil]octena kiselina
3-[5-(2-adamantilkarbamoil)-6-butil-piridin-2-il]-3-ezabiciklo[3.1.0]heksan-6-karboksilna kiselina 2-[(3S)-1-[6-butil-5-(cikloheksilkarbamoil)piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(cikloheksilkarbamoil)-6-ciklopropil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-(2-adamantilkarbamoil)-6-ciklopropil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-ciklopropil-5-[[(2r,5s)-5-hidroksi-2-adamantil]karbamoil]piridin-2-il]-3-piperidil]octena kiselina
2-[(3R)-1-[5-(cikloheksil-metil-karbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina 2-[(3S)-1-[5-(cikloheksil-metil-karbamoil)-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina [(3S)-1-{5-[((2r,5s)-5-methoksiadamantan-2-il)(metil)karbamoil]-6-(propilthio)piridin-2-il}piperidin-3-il]octena kiselina
[(3S)-1-{5-[((2r,5s)-5-hidroksiadamantan-2-il)(metil)karbamoil]-6-(propilthio)piridin-2-il}piperidin-3-il]octena kiselina
{(3S)-1-[5-(adamantan-1-ilcamamoil)-6-(propilthio)piridin-2-il]piperidin-3-il}octena kiselina {(3S)-1-[6-(propilthio)-5-((tetrahidro-2H-piran-4-ilkarbamoil)piridin-2-il]piperidin-3-il}octena kiselina
[(3S)-1-{5-[metil(tetrahidro-2H-piran-4-il)karbamoil]-6-(propilthio)piridin-2-il}piperidin-3-il]octena kiselina
2-[(3S)-1-[6-cikloheksilsulfanil-5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]piridin-2-il]pirolidin-3-il]octena kiselina
2-[(3S)-1-[6-cikloheksilsulfanil-5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[6-ciklopentilsulfanil-5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]piridin-2-il]pirolidin-3-il]octena kiselina
2-[(3S)-1-[6-ciklopentilsulfanil-5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]-3-piperidil]octena kiselina
2-[(3S)-1-[5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
2-[(3S)-1-[5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]-6-propoksi-piridin-Z-il]-3-piperidil]octena kiselina
(3R)-1-[6-ciklopentilsulfanil-5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]piridin-2-il]pirolidine-3-karboksilna kiselina
(1R,5S)-3-[6-ciklopentilsulfanil-5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]piridin-2-il]-3-azabiciklo[3.1.0]heksan-6-karboksilna kiselina
2-[(3R)-1-[5-[[(2r,5s)-5-(difluoromethoksi)-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]pirolidin-3-il]octena kiselina
1-[5-[[(2r,5s),5-(difluoromethoksi)-2-adamantil]karbamoil]-6-propilsulfanil-piridin-2-il]pirolidine-3-karboksilna kiselina
(S)-2-(1-(5-(cikloheksilkarbamoil)-3-fluoro-6-(propilthio)piridin-2-il)piperidin-3-il)octena kiselina ili (R)-2-(1-(5-(cikloheksilkarbamoil)-3-fluoro-6-(propilthio)piridin-2-il)piperidin-3-il)octena kiselinaili njegova farmaceutski prihvatljiva sol.
11. Farmaceutski pripravak, naznačen time da sadrži spoj prema zahtjevu1 u kombinaciji sa farmaceutski prihvatljivim otapalom ili nosačem.
12. Spoj prema zahtjevu 1, naznačen time da se koristi za postupak profilakse il terapijskog liječenja toplokrvnih životinja, kao čovjeka.
13. Spoj prema zahtjevu 1 naznačen time da je za upotrebu kao lijek.
14. Spoj prema zahtjevu 13, naznačen time da lijek je lijek za liječenje metaboličkih sindroma, dijabetesa tipa II, pretilosti ili ateroskleroze.
15. Upotreba spoja prema zahtjevu 1 naznačena time da se koristi za proizvodnju lijeka za upotrebu za dobivanje 11βHSD1 inhibicijskog efekta kod toplokrvnih životinja, kao čovjeka.
16. Postupak za dobivanje spoja prema zahtjevu 1, naznačen time da navedeni postupak [pri čemu Z je -X-Y-COOH i druge varijabilne skupine su, ukoliko nije drugačije navedeno, kako je definirano u formuli (1) u zahtjevu 1] uključuje bilo koji od postupaka a) do e):
a) reakciju spoja formule (2) sa spojem formule (3):
[image]
b) reakciju spoja formule (4) sa spojem formule (5):
[image]
pri čemu X je odlazna skupina; ili
c) reakciju spoja formule (6) sa spojem formule (7):
[image]
pri čemu X' je odlazna skupina; ili
d) reakciju spoja formule (8) sa spojem formule (9):
[image]
pri čemu X" je odlazna skupina; ili
e) reakciju spoja formule (10) sa spojem formule (11):
[image]
pri čemu X"' je odlazna skupina;
i nakon toga ako je potrebno ili poželjno:
i) pretvaranja spoja formule (1) u drugi spoj formule (1);
ii) uklanjanja bilo kojih zaštitnih skupina;
iii) rješavanja enantiomera;
iv) formiranja farmaceutski prihvatljive soli ili njihove in vivo hidrolizacije.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86424706P | 2006-11-03 | 2006-11-03 | |
US86430306P | 2006-11-03 | 2006-11-03 | |
PCT/GB2007/004131 WO2008053194A2 (en) | 2006-11-03 | 2007-10-31 | Pyridine carboxamides as 11-beta-hsd1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100522T1 true HRP20100522T1 (hr) | 2010-11-30 |
Family
ID=39304797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100522T HRP20100522T1 (hr) | 2006-11-03 | 2010-09-22 | Piridin karboksamidi kao inhibitori 11-beta-hsd1 |
Country Status (31)
Country | Link |
---|---|
US (3) | US7964618B2 (hr) |
EP (2) | EP2086939B8 (hr) |
JP (1) | JP5165688B2 (hr) |
KR (1) | KR101465275B1 (hr) |
CN (3) | CN101573336B (hr) |
AR (1) | AR063458A1 (hr) |
AT (1) | ATE475649T1 (hr) |
AU (1) | AU2007315955B2 (hr) |
BR (1) | BRPI0717970C1 (hr) |
CA (1) | CA2668006C (hr) |
CL (1) | CL2007003176A1 (hr) |
CO (1) | CO6321130A2 (hr) |
CY (1) | CY1110813T1 (hr) |
DE (1) | DE602007008137D1 (hr) |
DK (1) | DK2086939T3 (hr) |
ES (2) | ES2423206T3 (hr) |
HK (1) | HK1135090A1 (hr) |
HR (1) | HRP20100522T1 (hr) |
IL (1) | IL198231A0 (hr) |
MX (1) | MX2009004707A (hr) |
NO (1) | NO20091603L (hr) |
NZ (1) | NZ576501A (hr) |
PE (1) | PE20081487A1 (hr) |
PL (1) | PL2086939T3 (hr) |
PT (1) | PT2086939E (hr) |
RS (1) | RS51451B (hr) |
RU (1) | RU2451674C2 (hr) |
SI (1) | SI2086939T1 (hr) |
TW (1) | TW200827346A (hr) |
UY (1) | UY30681A1 (hr) |
WO (1) | WO2008053194A2 (hr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006316087B2 (en) | 2005-11-21 | 2011-03-10 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
TW200836719A (en) * | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
BRPI0811191A2 (pt) | 2007-05-18 | 2014-10-29 | Shionogi & Co | Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009051112A1 (ja) * | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | アミド化合物およびその用途 |
WO2009056881A1 (en) * | 2007-10-29 | 2009-05-07 | Astrazeneca Ab | Chemical compounds 313 |
KR20100126306A (ko) * | 2008-02-04 | 2010-12-01 | 아스트라제네카 아베 | 4-[4-(2-(아다만틸카르바모일)-5-tert-부틸-피라졸-1-일]벤조산의 신규한 결정형 |
CA2719936A1 (en) * | 2008-04-22 | 2009-10-29 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281 |
EP2243479A3 (en) | 2009-04-20 | 2011-01-19 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
UY32954A (es) * | 2009-10-20 | 2011-05-31 | Astrazeneca Ab | PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?. |
CA2780908A1 (en) * | 2009-11-24 | 2011-06-03 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
US8871208B2 (en) * | 2009-12-04 | 2014-10-28 | Abbvie Inc. | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
SG188307A1 (en) | 2010-09-23 | 2013-04-30 | Abbvie Inc | Monohydrate of an azaadamantane derivative |
US8471027B2 (en) * | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
EP2735567B1 (en) * | 2011-07-21 | 2016-10-26 | Xuanzhu Pharma Co., Ltd. | Heterocyclic substituted pyrimidine compound |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN102659657B (zh) * | 2012-04-24 | 2014-08-06 | 徐州医学院 | 一种蛋白酶抑制剂pf429242的合成方法 |
IN2014DN09348A (hr) | 2012-06-20 | 2015-07-17 | Hoffmann La Roche | |
IN2014DN09347A (hr) | 2012-06-20 | 2015-07-17 | Hoffmann La Roche | |
EP3821892A1 (en) * | 2019-11-12 | 2021-05-19 | University of Leeds | (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR66581B (hr) | 1978-02-21 | 1981-03-27 | Delalande Sa | |
US4734418A (en) | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
BRPI0014526C1 (pt) | 1999-09-16 | 2021-05-25 | Mitsubishi Tanabe Pharma Corp | compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo |
FR2803592A1 (fr) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
DK1383731T3 (da) | 2000-10-20 | 2009-12-07 | Biocryst Pharm Inc | Biarylforbindelser som serinproteaseinhibitorer |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
JP2005528395A (ja) | 2002-04-05 | 2005-09-22 | ザ ユニバーシティ オブ エディンバラ | 組成物 |
WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
TW200503994A (en) * | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
SE0300458D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
MXPA05009059A (es) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
EP1615698B1 (en) | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
CN1832741A (zh) | 2003-08-07 | 2006-09-13 | 默克公司 | 作为11-β-羟甾类脱氢酶-1抑制剂的吡唑甲酰胺类 |
AU2004270733B2 (en) | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
WO2005060963A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
ATE407119T1 (de) | 2004-02-24 | 2008-09-15 | Glaxo Group Ltd | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors |
US7423147B2 (en) * | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
MXPA06012831A (es) | 2004-05-06 | 2007-01-26 | Pfizer | Nuevos compuestos de derivados de morfolina y prolina. |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
PT1763517E (pt) | 2004-06-28 | 2011-07-01 | Hoffmann La Roche | Derivados de pirimidina como inibidores 11beta-hsd1 |
JP2008518903A (ja) | 2004-11-02 | 2008-06-05 | ファイザー・インク | 置換および非置換アダマンチルアミドの新規化合物 |
WO2006050476A2 (en) | 2004-11-03 | 2006-05-11 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as ion channel modulators and methods of use |
EP1846363B1 (en) | 2005-01-05 | 2012-04-25 | Abbott Laboratories | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
PL1928840T3 (pl) | 2005-04-05 | 2012-01-31 | Hoffmann La Roche | 1H-pirazolo-4-karboksyamidy, ich wytwarzanie i ich zastosowanie jako inhibitory dehydrogenazy 11-beta-hydroksysteroidowej |
MX2007012213A (es) | 2005-04-06 | 2007-12-10 | Hoffmann La Roche | Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides. |
WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
JP2008542247A (ja) | 2005-05-24 | 2008-11-27 | アストラゼネカ アクチボラグ | グルコキナーゼモジュレーターとしての2−フェニル置換イミダゾール[4,5b]ピリジン/ピラジンおよびプリン誘導体 |
WO2006132197A1 (ja) | 2005-06-07 | 2006-12-14 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
WO2006132436A1 (ja) | 2005-06-08 | 2006-12-14 | Japan Tobacco Inc. | 複素環化合物 |
EA200702498A1 (ru) | 2005-06-16 | 2008-06-30 | Пфайзер Инк. | N-(пиридин-2-ил)сульфонамидные производные |
NZ575514A (en) | 2005-07-09 | 2009-11-27 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
JP2009504621A (ja) | 2005-08-09 | 2009-02-05 | アストラゼネカ アクチボラグ | 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体 |
CA2627813A1 (en) | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
AU2006316087B2 (en) | 2005-11-21 | 2011-03-10 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I |
WO2007089683A1 (en) | 2006-01-31 | 2007-08-09 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
KR20110007258A (ko) | 2006-03-22 | 2011-01-21 | 에프. 호프만-라 로슈 아게 | 11-베타-hsd-1로서의 피라졸 |
BRPI0710669A2 (pt) | 2006-04-07 | 2011-08-16 | High Point Pharmaceuticals Llc | compostos ativos de dehidrogenase de 11b-hidroxiesteróide tipo 1 |
JP2009534440A (ja) | 2006-04-27 | 2009-09-24 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | カリウムチャンネルモジュレーターとしてのcbxカンナビノイド受容体モジュレーターの使用 |
WO2008012532A2 (en) | 2006-07-27 | 2008-01-31 | Astrazeneca Ab | : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
BRPI0811191A2 (pt) | 2007-05-18 | 2014-10-29 | Shionogi & Co | Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1 |
ES2423181T3 (es) | 2007-07-17 | 2013-09-18 | F. Hoffmann-La Roche Ag | Inhibidores de la 11ß-hidroxiesteroide-deshidrogenasa |
US20110060022A1 (en) * | 2007-11-06 | 2011-03-10 | Astrazeneca Ab | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic Acid - 465 |
KR20100126306A (ko) | 2008-02-04 | 2010-12-01 | 아스트라제네카 아베 | 4-[4-(2-(아다만틸카르바모일)-5-tert-부틸-피라졸-1-일]벤조산의 신규한 결정형 |
CA2719936A1 (en) | 2008-04-22 | 2009-10-29 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281 |
EP2391607A1 (en) | 2009-01-30 | 2011-12-07 | AstraZeneca AB | Novel process for preparing carboxy-containing pyrazoleamido compounds 597 |
UY32954A (es) * | 2009-10-20 | 2011-05-31 | Astrazeneca Ab | PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?. |
-
2007
- 2007-10-29 TW TW096140633A patent/TW200827346A/zh unknown
- 2007-10-30 US US11/928,744 patent/US7964618B2/en active Active
- 2007-10-31 BR BRPI0717970A patent/BRPI0717970C1/pt active IP Right Grant
- 2007-10-31 AT AT07824375T patent/ATE475649T1/de active
- 2007-10-31 KR KR1020097010339A patent/KR101465275B1/ko active IP Right Grant
- 2007-10-31 PL PL07824375T patent/PL2086939T3/pl unknown
- 2007-10-31 DK DK07824375.5T patent/DK2086939T3/da active
- 2007-10-31 DE DE602007008137T patent/DE602007008137D1/de active Active
- 2007-10-31 RS RSP-2010/0422A patent/RS51451B/en unknown
- 2007-10-31 JP JP2009535119A patent/JP5165688B2/ja active Active
- 2007-10-31 RU RU2009115830/04A patent/RU2451674C2/ru active
- 2007-10-31 EP EP07824375A patent/EP2086939B8/en active Active
- 2007-10-31 WO PCT/GB2007/004131 patent/WO2008053194A2/en active Application Filing
- 2007-10-31 MX MX2009004707A patent/MX2009004707A/es active IP Right Grant
- 2007-10-31 CA CA2668006A patent/CA2668006C/en active Active
- 2007-10-31 SI SI200730335T patent/SI2086939T1/sl unknown
- 2007-10-31 ES ES10163730T patent/ES2423206T3/es active Active
- 2007-10-31 EP EP10163730.4A patent/EP2233480B1/en active Active
- 2007-10-31 CN CN2007800491675A patent/CN101573336B/zh not_active Expired - Fee Related
- 2007-10-31 AU AU2007315955A patent/AU2007315955B2/en active Active
- 2007-10-31 NZ NZ576501A patent/NZ576501A/en not_active IP Right Cessation
- 2007-10-31 CN CN2012100119350A patent/CN102603711A/zh active Pending
- 2007-10-31 PT PT07824375T patent/PT2086939E/pt unknown
- 2007-10-31 ES ES07824375T patent/ES2347491T3/es active Active
- 2007-10-31 UY UY30681A patent/UY30681A1/es not_active Application Discontinuation
- 2007-10-31 CN CN2010101438299A patent/CN101787016B/zh active Active
- 2007-11-02 AR ARP070104887A patent/AR063458A1/es not_active Application Discontinuation
- 2007-11-02 CL CL200703176A patent/CL2007003176A1/es unknown
- 2007-11-05 PE PE2007001517A patent/PE20081487A1/es not_active Application Discontinuation
-
2009
- 2009-04-20 IL IL198231A patent/IL198231A0/en unknown
- 2009-04-22 NO NO20091603A patent/NO20091603L/no not_active Application Discontinuation
- 2009-04-29 CO CO09043382A patent/CO6321130A2/es not_active Application Discontinuation
- 2009-08-14 US US12/541,565 patent/US8673938B2/en active Active
- 2009-08-14 US US12/541,574 patent/US20090312372A1/en not_active Abandoned
-
2010
- 2010-02-09 HK HK10101460.7A patent/HK1135090A1/xx unknown
- 2010-09-22 HR HR20100522T patent/HRP20100522T1/hr unknown
- 2010-10-04 CY CY20101100879T patent/CY1110813T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100522T1 (hr) | Piridin karboksamidi kao inhibitori 11-beta-hsd1 | |
JP2010508338A5 (hr) | ||
RU2019132254A (ru) | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca | |
JP2006500348A5 (hr) | ||
HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
JP6644765B2 (ja) | プロテインキナーゼc阻害剤およびその使用方法 | |
RU2011107437A (ru) | Ингибиторы кинуренин-3-моноксигеназы | |
JP2019505595A5 (hr) | ||
RU2010137114A (ru) | Амидные производные как позитивные аллостерические модуляторы и способы их применения | |
HRP20120240T1 (hr) | Piridil piperidin antagonisti receptora za oreksin | |
RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
HRP20100153T1 (hr) | Antagonisti kemokin receptora | |
RU2013154117A (ru) | Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы | |
RU2017126199A (ru) | Биарильное производное в качестве агониста gpr120 | |
RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
EA026851B1 (ru) | Циклические амиды в качестве ингибиторов метар-2 | |
HRP20140252T1 (hr) | Derivati imidazola kao inhibitori kazeinske kinaze | |
JP2018515489A5 (hr) | ||
HRP20161797T1 (hr) | Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina | |
ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
NZ630488A (en) | Piperidine derivatives for gpr119 agonist | |
RU2010106974A (ru) | Ариловые эфиры пирролидина в качестве антагонистов рецепторов nk3 | |
HRP20140588T1 (hr) | Spojevi kondenziranog prstena i njihova uporaba | |
HRP20230313T1 (hr) | Modulatori receptora cxcr7 piperidina |